nodes	percent_of_prediction	percent_of_DWPC	metapath
Lovastatin—UGT2B7—Mycophenolic acid—systemic scleroderma	0.122	0.172	CbGbCtD
Lovastatin—UGT1A1—Mycophenolic acid—systemic scleroderma	0.106	0.148	CbGbCtD
Lovastatin—UGT2B7—Mycophenolate mofetil—systemic scleroderma	0.0683	0.0959	CbGbCtD
Lovastatin—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.059	0.0829	CbGbCtD
Lovastatin—CYP2C8—Mometasone—systemic scleroderma	0.0434	0.061	CbGbCtD
Lovastatin—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.0408	0.0574	CbGbCtD
Lovastatin—ABCC2—Mycophenolate mofetil—systemic scleroderma	0.0359	0.0504	CbGbCtD
Lovastatin—SLCO1A2—Prednisone—systemic scleroderma	0.0346	0.0487	CbGbCtD
Lovastatin—ABCB1—Lisinopril—systemic scleroderma	0.0199	0.0279	CbGbCtD
Lovastatin—CYP2C9—Leflunomide—systemic scleroderma	0.0195	0.0274	CbGbCtD
Lovastatin—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.018	0.0253	CbGbCtD
Lovastatin—SLCO1A2—Methotrexate—systemic scleroderma	0.0174	0.0244	CbGbCtD
Lovastatin—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0173	0.0243	CbGbCtD
Lovastatin—SLCO1B1—Methotrexate—systemic scleroderma	0.0164	0.023	CbGbCtD
Lovastatin—ABCB1—Captopril—systemic scleroderma	0.0149	0.0209	CbGbCtD
Lovastatin—ABCC2—Methotrexate—systemic scleroderma	0.0144	0.0202	CbGbCtD
Lovastatin—CYP2D6—Captopril—systemic scleroderma	0.014	0.0197	CbGbCtD
Lovastatin—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0117	0.0164	CbGbCtD
Lovastatin—CYP2C19—Prednisone—systemic scleroderma	0.0116	0.0163	CbGbCtD
Lovastatin—ABCB1—Prednisone—systemic scleroderma	0.00935	0.0131	CbGbCtD
Lovastatin—CYP2C9—cardial valve—systemic scleroderma	0.00922	0.16	CbGeAlD
Lovastatin—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00701	0.00985	CbGbCtD
Lovastatin—ITGAL—endothelium—systemic scleroderma	0.0067	0.116	CbGeAlD
Lovastatin—ITGAL—blood vessel—systemic scleroderma	0.00617	0.107	CbGeAlD
Lovastatin—CYP3A4—Prednisone—systemic scleroderma	0.0056	0.00788	CbGbCtD
Lovastatin—ITGAL—Beta2 integrin cell surface interactions—TGFBI—systemic scleroderma	0.00483	0.0827	CbGpPWpGaD
Lovastatin—ABCB1—Methotrexate—systemic scleroderma	0.00469	0.0066	CbGbCtD
Lovastatin—ITGAL—Integrin-mediated Cell Adhesion—GIT2—systemic scleroderma	0.00419	0.0718	CbGpPWpGaD
Lovastatin—ITGAL—Integrin family cell surface interactions—ITGAM—systemic scleroderma	0.00382	0.0654	CbGpPWpGaD
Lovastatin—ITGAL—Beta2 integrin cell surface interactions—ITGAM—systemic scleroderma	0.0035	0.0599	CbGpPWpGaD
Lovastatin—HDAC2—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.00344	1	CbGdCrCtD
Lovastatin—ITGAL—connective tissue—systemic scleroderma	0.00317	0.0549	CbGeAlD
Lovastatin—ITGAL—Integrin cell surface interactions—FBN1—systemic scleroderma	0.00285	0.0489	CbGpPWpGaD
Lovastatin—ITGAL—digestive system—systemic scleroderma	0.00229	0.0397	CbGeAlD
Lovastatin—ITGAL—tendon—systemic scleroderma	0.00218	0.0377	CbGeAlD
Lovastatin—PON3—tendon—systemic scleroderma	0.00213	0.037	CbGeAlD
Lovastatin—ITGAL—Beta2 integrin cell surface interactions—CD40LG—systemic scleroderma	0.00206	0.0353	CbGpPWpGaD
Lovastatin—ITGAL—Integrin cell surface interactions—HSPG2—systemic scleroderma	0.002	0.0342	CbGpPWpGaD
Lovastatin—UGT1A3—digestive system—systemic scleroderma	0.00194	0.0337	CbGeAlD
Lovastatin—ITGAL—lung—systemic scleroderma	0.00191	0.0331	CbGeAlD
Lovastatin—PON3—lung—systemic scleroderma	0.00187	0.0325	CbGeAlD
Lovastatin—ITGAL—Integrin cell surface interactions—ITGAM—systemic scleroderma	0.00181	0.031	CbGpPWpGaD
Lovastatin—ITGAL—Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell—CD247—systemic scleroderma	0.00173	0.0296	CbGpPWpGaD
Lovastatin—ITGAL—Cell surface interactions at the vascular wall—SELP—systemic scleroderma	0.00164	0.0281	CbGpPWpGaD
Lovastatin—ITGAL—Integrin-mediated Cell Adhesion—CSK—systemic scleroderma	0.00138	0.0237	CbGpPWpGaD
Lovastatin—ITGAL—Cell surface interactions at the vascular wall—ITGAM—systemic scleroderma	0.00131	0.0224	CbGpPWpGaD
Lovastatin—ITGAL—Integrin-mediated Cell Adhesion—ITGAM—systemic scleroderma	0.0013	0.0223	CbGpPWpGaD
Lovastatin—HDAC2—connective tissue—systemic scleroderma	0.00127	0.0219	CbGeAlD
Lovastatin—HDAC2—smooth muscle tissue—systemic scleroderma	0.00116	0.0201	CbGeAlD
Lovastatin—HDAC2—skin of body—systemic scleroderma	0.00114	0.0198	CbGeAlD
Lovastatin—HMGCR—connective tissue—systemic scleroderma	0.00114	0.0198	CbGeAlD
Lovastatin—UGT2B7—digestive system—systemic scleroderma	0.00112	0.0194	CbGeAlD
Lovastatin—HMGCR—smooth muscle tissue—systemic scleroderma	0.00104	0.0181	CbGeAlD
Lovastatin—HMGCR—skin of body—systemic scleroderma	0.00103	0.0179	CbGeAlD
Lovastatin—ITGAL—Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell—CD40LG—systemic scleroderma	0.00102	0.0174	CbGpPWpGaD
Lovastatin—UGT1A1—digestive system—systemic scleroderma	0.00095	0.0165	CbGeAlD
Lovastatin—ITGAL—Extracellular matrix organization—FBN1—systemic scleroderma	0.000941	0.0161	CbGpPWpGaD
Lovastatin—HDAC2—digestive system—systemic scleroderma	0.000914	0.0159	CbGeAlD
Lovastatin—ITGAL—Focal Adhesion—RHOB—systemic scleroderma	0.000908	0.0156	CbGpPWpGaD
Lovastatin—HDAC2—tendon—systemic scleroderma	0.00087	0.0151	CbGeAlD
Lovastatin—ITGAL—Focal Adhesion—COL1A2—systemic scleroderma	0.000856	0.0147	CbGpPWpGaD
Lovastatin—HMGCR—digestive system—systemic scleroderma	0.000825	0.0143	CbGeAlD
Lovastatin—HDAC2—Signaling events mediated by HDAC Class I—SMAD7—systemic scleroderma	0.000802	0.0137	CbGpPWpGaD
Lovastatin—SLCO1B1—digestive system—systemic scleroderma	0.00079	0.0137	CbGeAlD
Lovastatin—HMGCR—tendon—systemic scleroderma	0.000785	0.0136	CbGeAlD
Lovastatin—ITGAL—Focal Adhesion—ITGAM—systemic scleroderma	0.000778	0.0133	CbGpPWpGaD
Lovastatin—HDAC2—lung—systemic scleroderma	0.000763	0.0132	CbGeAlD
Lovastatin—ITGAL—Focal Adhesion—BLK—systemic scleroderma	0.00072	0.0123	CbGpPWpGaD
Lovastatin—HDAC2—Regulation of nuclear SMAD2/3 signaling—SMAD7—systemic scleroderma	0.000714	0.0122	CbGpPWpGaD
Lovastatin—HMGCR—lung—systemic scleroderma	0.000689	0.0119	CbGeAlD
Lovastatin—ITGAL—Extracellular matrix organization—COL1A2—systemic scleroderma	0.000658	0.0113	CbGpPWpGaD
Lovastatin—ITGAL—Extracellular matrix organization—HSPG2—systemic scleroderma	0.000658	0.0113	CbGpPWpGaD
Lovastatin—ITGAL—Cell surface interactions at the vascular wall—MMP1—systemic scleroderma	0.000657	0.0112	CbGpPWpGaD
Lovastatin—SLCO1A2—digestive system—systemic scleroderma	0.000643	0.0112	CbGeAlD
Lovastatin—ABCC2—digestive system—systemic scleroderma	0.000599	0.0104	CbGeAlD
Lovastatin—ITGAL—Extracellular matrix organization—ITGAM—systemic scleroderma	0.000598	0.0102	CbGpPWpGaD
Lovastatin—ABCB1—blood vessel—systemic scleroderma	0.000582	0.0101	CbGeAlD
Lovastatin—ABCC2—tendon—systemic scleroderma	0.00057	0.00989	CbGeAlD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000542	0.00929	CbGpPWpGaD
Lovastatin—SLCO1A2—lung—systemic scleroderma	0.000537	0.00931	CbGeAlD
Lovastatin—HDAC2—Regulation of nuclear SMAD2/3 signaling—COL1A2—systemic scleroderma	0.000521	0.00892	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—GDF15—systemic scleroderma	0.000517	0.00885	CbGpPWpGaD
Lovastatin—CYP2C19—digestive system—systemic scleroderma	0.000515	0.00893	CbGeAlD
Lovastatin—HDAC2—Neural Crest Differentiation—RHOB—systemic scleroderma	0.000463	0.00792	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—SELP—systemic scleroderma	0.000444	0.00761	CbGpPWpGaD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—IL13—systemic scleroderma	0.000441	0.00755	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—RHOB—systemic scleroderma	0.000415	0.0071	CbGpPWpGaD
Lovastatin—CYP3A5—digestive system—systemic scleroderma	0.000405	0.00703	CbGeAlD
Lovastatin—CYP2C9—digestive system—systemic scleroderma	0.000399	0.00692	CbGeAlD
Lovastatin—HDAC2—Circadian rythm related genes—TOP1—systemic scleroderma	0.000387	0.00663	CbGpPWpGaD
Lovastatin—HMGCR—PPARA activates gene expression—CTGF—systemic scleroderma	0.000386	0.00662	CbGpPWpGaD
Lovastatin—HMGCR—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—systemic scleroderma	0.000378	0.00648	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—CSK—systemic scleroderma	0.000378	0.00647	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—ITGAM—systemic scleroderma	0.000355	0.00608	CbGpPWpGaD
Lovastatin—CYP3A5—lung—systemic scleroderma	0.000339	0.00587	CbGeAlD
Lovastatin—ITGAL—Adaptive Immune System—CSK—systemic scleroderma	0.000327	0.00559	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—IRF5—systemic scleroderma	0.000319	0.00547	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—CD247—systemic scleroderma	0.000307	0.00526	CbGpPWpGaD
Lovastatin—CYP3A4—digestive system—systemic scleroderma	0.000304	0.00528	CbGeAlD
Lovastatin—ITGAL—Extracellular matrix organization—MMP1—systemic scleroderma	0.0003	0.00513	CbGpPWpGaD
Lovastatin—CYP2D6—digestive system—systemic scleroderma	0.000299	0.00519	CbGeAlD
Lovastatin—ITGAL—Adaptive Immune System—BLK—systemic scleroderma	0.000284	0.00487	CbGpPWpGaD
Lovastatin—HMGCR—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	0.000261	0.00446	CbGpPWpGaD
Lovastatin—Nausea—Pentoxifylline—systemic scleroderma	0.000236	0.0014	CcSEcCtD
Lovastatin—Chills—Mycophenolate mofetil—systemic scleroderma	0.000236	0.0014	CcSEcCtD
Lovastatin—Malaise—Lisinopril—systemic scleroderma	0.000236	0.00139	CcSEcCtD
Lovastatin—Infection—Mycophenolic acid—systemic scleroderma	0.000235	0.00139	CcSEcCtD
Lovastatin—Vertigo—Lisinopril—systemic scleroderma	0.000235	0.00139	CcSEcCtD
Lovastatin—Diarrhoea—Mometasone—systemic scleroderma	0.000235	0.00139	CcSEcCtD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	0.000235	0.00402	CbGpPWpGaD
Lovastatin—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000234	0.00401	CbGpPWpGaD
Lovastatin—Leukopenia—Lisinopril—systemic scleroderma	0.000234	0.00138	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—CTLA4—systemic scleroderma	0.000233	0.00399	CbGpPWpGaD
Lovastatin—Alopecia—Mycophenolate mofetil—systemic scleroderma	0.000232	0.00138	CcSEcCtD
Lovastatin—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.000232	0.00137	CcSEcCtD
Lovastatin—ITGAL—Extracellular matrix organization—MMP2—systemic scleroderma	0.000232	0.00397	CbGpPWpGaD
Lovastatin—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000226	0.00134	CcSEcCtD
Lovastatin—Anorexia—Mycophenolic acid—systemic scleroderma	0.000226	0.00134	CcSEcCtD
Lovastatin—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000226	0.00134	CcSEcCtD
Lovastatin—Insomnia—Leflunomide—systemic scleroderma	0.000225	0.00133	CcSEcCtD
Lovastatin—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000224	0.00133	CcSEcCtD
Lovastatin—Paraesthesia—Leflunomide—systemic scleroderma	0.000223	0.00132	CcSEcCtD
Lovastatin—Arthralgia—Lisinopril—systemic scleroderma	0.000223	0.00132	CcSEcCtD
Lovastatin—Myalgia—Lisinopril—systemic scleroderma	0.000223	0.00132	CcSEcCtD
Lovastatin—Chest pain—Lisinopril—systemic scleroderma	0.000223	0.00132	CcSEcCtD
Lovastatin—Anxiety—Lisinopril—systemic scleroderma	0.000222	0.00131	CcSEcCtD
Lovastatin—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000222	0.00131	CcSEcCtD
Lovastatin—Dyspnoea—Leflunomide—systemic scleroderma	0.000221	0.00131	CcSEcCtD
Lovastatin—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.00022	0.0013	CcSEcCtD
Lovastatin—Discomfort—Lisinopril—systemic scleroderma	0.00022	0.0013	CcSEcCtD
Lovastatin—Dyspepsia—Leflunomide—systemic scleroderma	0.000219	0.00129	CcSEcCtD
Lovastatin—Pancreatitis—Prednisone—systemic scleroderma	0.000218	0.00129	CcSEcCtD
Lovastatin—Vomiting—Mometasone—systemic scleroderma	0.000218	0.00129	CcSEcCtD
Lovastatin—Dry mouth—Lisinopril—systemic scleroderma	0.000218	0.00129	CcSEcCtD
Lovastatin—Feeling abnormal—Azathioprine—systemic scleroderma	0.000217	0.00128	CcSEcCtD
Lovastatin—Rash—Mometasone—systemic scleroderma	0.000216	0.00128	CcSEcCtD
Lovastatin—Asthenia—Captopril—systemic scleroderma	0.000216	0.00128	CcSEcCtD
Lovastatin—Dermatitis—Mometasone—systemic scleroderma	0.000216	0.00128	CcSEcCtD
Lovastatin—Decreased appetite—Leflunomide—systemic scleroderma	0.000216	0.00128	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000216	0.00128	CcSEcCtD
Lovastatin—ABCB1—digestive system—systemic scleroderma	0.000215	0.00374	CbGeAlD
Lovastatin—Confusional state—Lisinopril—systemic scleroderma	0.000215	0.00127	CcSEcCtD
Lovastatin—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000215	0.00127	CcSEcCtD
Lovastatin—Headache—Mometasone—systemic scleroderma	0.000215	0.00127	CcSEcCtD
Lovastatin—Tremor—Mycophenolate mofetil—systemic scleroderma	0.000215	0.00127	CcSEcCtD
Lovastatin—Insomnia—Mycophenolic acid—systemic scleroderma	0.000214	0.00127	CcSEcCtD
Lovastatin—Fatigue—Leflunomide—systemic scleroderma	0.000214	0.00127	CcSEcCtD
Lovastatin—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000213	0.00126	CcSEcCtD
Lovastatin—Pruritus—Captopril—systemic scleroderma	0.000213	0.00126	CcSEcCtD
Lovastatin—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000213	0.00126	CcSEcCtD
Lovastatin—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000212	0.00126	CcSEcCtD
Lovastatin—CYP2C19—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000212	0.00364	CbGpPWpGaD
Lovastatin—Pain—Leflunomide—systemic scleroderma	0.000212	0.00126	CcSEcCtD
Lovastatin—Constipation—Leflunomide—systemic scleroderma	0.000212	0.00126	CcSEcCtD
Lovastatin—Infection—Lisinopril—systemic scleroderma	0.000212	0.00125	CcSEcCtD
Lovastatin—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000211	0.00125	CcSEcCtD
Lovastatin—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000209	0.00124	CcSEcCtD
Lovastatin—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000209	0.00124	CcSEcCtD
Lovastatin—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000208	0.00123	CcSEcCtD
Lovastatin—Abdominal pain—Azathioprine—systemic scleroderma	0.000208	0.00123	CcSEcCtD
Lovastatin—Body temperature increased—Azathioprine—systemic scleroderma	0.000208	0.00123	CcSEcCtD
Lovastatin—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000207	0.00122	CcSEcCtD
Lovastatin—Diarrhoea—Captopril—systemic scleroderma	0.000206	0.00122	CcSEcCtD
Lovastatin—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000206	0.00122	CcSEcCtD
Lovastatin—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000206	0.00122	CcSEcCtD
Lovastatin—Erectile dysfunction—Prednisone—systemic scleroderma	0.000205	0.00121	CcSEcCtD
Lovastatin—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000205	0.00121	CcSEcCtD
Lovastatin—Feeling abnormal—Leflunomide—systemic scleroderma	0.000205	0.00121	CcSEcCtD
Lovastatin—Fatigue—Mycophenolic acid—systemic scleroderma	0.000204	0.00121	CcSEcCtD
Lovastatin—Nausea—Mometasone—systemic scleroderma	0.000204	0.00121	CcSEcCtD
Lovastatin—Anorexia—Lisinopril—systemic scleroderma	0.000203	0.0012	CcSEcCtD
Lovastatin—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000203	0.0012	CcSEcCtD
Lovastatin—Pain—Mycophenolic acid—systemic scleroderma	0.000203	0.0012	CcSEcCtD
Lovastatin—Constipation—Mycophenolic acid—systemic scleroderma	0.000203	0.0012	CcSEcCtD
Lovastatin—Dizziness—Captopril—systemic scleroderma	0.000199	0.00118	CcSEcCtD
Lovastatin—ITGAL—Immune System—CSK—systemic scleroderma	0.000198	0.00339	CbGpPWpGaD
Lovastatin—Urticaria—Leflunomide—systemic scleroderma	0.000197	0.00117	CcSEcCtD
Lovastatin—Abdominal pain—Leflunomide—systemic scleroderma	0.000196	0.00116	CcSEcCtD
Lovastatin—Body temperature increased—Leflunomide—systemic scleroderma	0.000196	0.00116	CcSEcCtD
Lovastatin—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000195	0.00334	CbGpPWpGaD
Lovastatin—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000195	0.00115	CcSEcCtD
Lovastatin—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000195	0.00115	CcSEcCtD
Lovastatin—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000195	0.00115	CcSEcCtD
Lovastatin—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000195	0.00115	CcSEcCtD
Lovastatin—ITGAL—Immune System—IRF5—systemic scleroderma	0.000195	0.00334	CbGpPWpGaD
Lovastatin—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000195	0.00115	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000194	0.00115	CcSEcCtD
Lovastatin—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000194	0.00115	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000194	0.00115	CcSEcCtD
Lovastatin—Hypersensitivity—Azathioprine—systemic scleroderma	0.000194	0.00115	CcSEcCtD
Lovastatin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000194	0.00115	CcSEcCtD
Lovastatin—Insomnia—Lisinopril—systemic scleroderma	0.000193	0.00114	CcSEcCtD
Lovastatin—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000193	0.00114	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000192	0.00328	CbGpPWpGaD
Lovastatin—Paraesthesia—Lisinopril—systemic scleroderma	0.000192	0.00113	CcSEcCtD
Lovastatin—Vomiting—Captopril—systemic scleroderma	0.000192	0.00113	CcSEcCtD
Lovastatin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000191	0.00113	CcSEcCtD
Lovastatin—Dyspnoea—Lisinopril—systemic scleroderma	0.00019	0.00113	CcSEcCtD
Lovastatin—Rash—Captopril—systemic scleroderma	0.00019	0.00112	CcSEcCtD
Lovastatin—Dermatitis—Captopril—systemic scleroderma	0.00019	0.00112	CcSEcCtD
Lovastatin—Headache—Captopril—systemic scleroderma	0.000189	0.00112	CcSEcCtD
Lovastatin—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000188	0.00111	CcSEcCtD
Lovastatin—Dyspepsia—Lisinopril—systemic scleroderma	0.000188	0.00111	CcSEcCtD
Lovastatin—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000187	0.00111	CcSEcCtD
Lovastatin—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000187	0.00111	CcSEcCtD
Lovastatin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000187	0.00111	CcSEcCtD
Lovastatin—ITGAL—Immune System—IRF8—systemic scleroderma	0.000186	0.00319	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—CD247—systemic scleroderma	0.000186	0.00319	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—ITGAM—systemic scleroderma	0.000186	0.00319	CbGpPWpGaD
Lovastatin—Infection—Mycophenolate mofetil—systemic scleroderma	0.000186	0.0011	CcSEcCtD
Lovastatin—Decreased appetite—Lisinopril—systemic scleroderma	0.000185	0.0011	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—systemic scleroderma	0.000185	0.00317	CbGpPWpGaD
Lovastatin—Eosinophilia—Methotrexate—systemic scleroderma	0.000184	0.00109	CcSEcCtD
Lovastatin—Fatigue—Lisinopril—systemic scleroderma	0.000184	0.00109	CcSEcCtD
Lovastatin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000183	0.00108	CcSEcCtD
Lovastatin—Hypersensitivity—Leflunomide—systemic scleroderma	0.000183	0.00108	CcSEcCtD
Lovastatin—Pancreatitis—Methotrexate—systemic scleroderma	0.000183	0.00108	CcSEcCtD
Lovastatin—Constipation—Lisinopril—systemic scleroderma	0.000182	0.00108	CcSEcCtD
Lovastatin—Pain—Lisinopril—systemic scleroderma	0.000182	0.00108	CcSEcCtD
Lovastatin—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000182	0.00312	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—CD40LG—systemic scleroderma	0.000181	0.0031	CbGpPWpGaD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.00018	0.00308	CbGpPWpGaD
Lovastatin—ABCB1—lung—systemic scleroderma	0.00018	0.00312	CbGeAlD
Lovastatin—Diarrhoea—Azathioprine—systemic scleroderma	0.00018	0.00106	CcSEcCtD
Lovastatin—Nausea—Captopril—systemic scleroderma	0.000179	0.00106	CcSEcCtD
Lovastatin—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000178	0.00106	CcSEcCtD
Lovastatin—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000178	0.00105	CcSEcCtD
Lovastatin—Asthenia—Leflunomide—systemic scleroderma	0.000178	0.00105	CcSEcCtD
Lovastatin—ITGAL—Hemostasis—MMP1—systemic scleroderma	0.000178	0.00305	CbGpPWpGaD
Lovastatin—Feeling abnormal—Lisinopril—systemic scleroderma	0.000176	0.00104	CcSEcCtD
Lovastatin—Pruritus—Leflunomide—systemic scleroderma	0.000176	0.00104	CcSEcCtD
Lovastatin—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000174	0.00103	CcSEcCtD
Lovastatin—ITGAL—Immune System—TNFAIP3—systemic scleroderma	0.000174	0.00299	CbGpPWpGaD
Lovastatin—ITGAL—Extracellular matrix organization—MMP9—systemic scleroderma	0.000174	0.00298	CbGpPWpGaD
Lovastatin—Dizziness—Azathioprine—systemic scleroderma	0.000174	0.00103	CcSEcCtD
Lovastatin—ITGAL—Immune System—BLK—systemic scleroderma	0.000172	0.00295	CbGpPWpGaD
Lovastatin—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000171	0.00101	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00017	0.00101	CcSEcCtD
Lovastatin—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.00017	0.00101	CcSEcCtD
Lovastatin—Asthenia—Mycophenolic acid—systemic scleroderma	0.00017	0.00101	CcSEcCtD
Lovastatin—Diarrhoea—Leflunomide—systemic scleroderma	0.00017	0.001	CcSEcCtD
Lovastatin—Urticaria—Lisinopril—systemic scleroderma	0.000169	0.001	CcSEcCtD
Lovastatin—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000169	0.001	CcSEcCtD
Lovastatin—Abdominal pain—Lisinopril—systemic scleroderma	0.000169	0.000998	CcSEcCtD
Lovastatin—Body temperature increased—Lisinopril—systemic scleroderma	0.000169	0.000998	CcSEcCtD
Lovastatin—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000168	0.000993	CcSEcCtD
Lovastatin—Pruritus—Mycophenolic acid—systemic scleroderma	0.000168	0.000991	CcSEcCtD
Lovastatin—Vomiting—Azathioprine—systemic scleroderma	0.000167	0.000989	CcSEcCtD
Lovastatin—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000986	CcSEcCtD
Lovastatin—Rash—Azathioprine—systemic scleroderma	0.000166	0.000981	CcSEcCtD
Lovastatin—Dermatitis—Azathioprine—systemic scleroderma	0.000166	0.00098	CcSEcCtD
Lovastatin—Flushing—Prednisone—systemic scleroderma	0.000165	0.000979	CcSEcCtD
Lovastatin—Headache—Azathioprine—systemic scleroderma	0.000165	0.000974	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000165	0.000974	CcSEcCtD
Lovastatin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000165	0.000973	CcSEcCtD
Lovastatin—Dizziness—Leflunomide—systemic scleroderma	0.000164	0.000971	CcSEcCtD
Lovastatin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000162	0.000961	CcSEcCtD
Lovastatin—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000162	0.000959	CcSEcCtD
Lovastatin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	0.000162	0.00277	CbGpPWpGaD
Lovastatin—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00016	0.000946	CcSEcCtD
Lovastatin—Pain—Mycophenolate mofetil—systemic scleroderma	0.00016	0.000946	CcSEcCtD
Lovastatin—Vomiting—Leflunomide—systemic scleroderma	0.000158	0.000934	CcSEcCtD
Lovastatin—Alopecia—Prednisone—systemic scleroderma	0.000158	0.000932	CcSEcCtD
Lovastatin—Hypersensitivity—Lisinopril—systemic scleroderma	0.000157	0.00093	CcSEcCtD
Lovastatin—Dizziness—Mycophenolic acid—systemic scleroderma	0.000157	0.000927	CcSEcCtD
Lovastatin—Rash—Leflunomide—systemic scleroderma	0.000157	0.000926	CcSEcCtD
Lovastatin—Dermatitis—Leflunomide—systemic scleroderma	0.000156	0.000925	CcSEcCtD
Lovastatin—Nausea—Azathioprine—systemic scleroderma	0.000156	0.000924	CcSEcCtD
Lovastatin—Headache—Leflunomide—systemic scleroderma	0.000156	0.00092	CcSEcCtD
Lovastatin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000911	CcSEcCtD
Lovastatin—Asthenia—Lisinopril—systemic scleroderma	0.000153	0.000905	CcSEcCtD
Lovastatin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000153	0.000904	CcSEcCtD
Lovastatin—Pruritus—Lisinopril—systemic scleroderma	0.000151	0.000893	CcSEcCtD
Lovastatin—Vomiting—Mycophenolic acid—systemic scleroderma	0.000151	0.000891	CcSEcCtD
Lovastatin—Rash—Mycophenolic acid—systemic scleroderma	0.000149	0.000883	CcSEcCtD
Lovastatin—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000149	0.000883	CcSEcCtD
Lovastatin—Hepatitis—Methotrexate—systemic scleroderma	0.000149	0.000882	CcSEcCtD
Lovastatin—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000148	0.000878	CcSEcCtD
Lovastatin—Headache—Mycophenolic acid—systemic scleroderma	0.000148	0.000878	CcSEcCtD
Lovastatin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000148	0.000874	CcSEcCtD
Lovastatin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000148	0.000874	CcSEcCtD
Lovastatin—Nausea—Leflunomide—systemic scleroderma	0.000147	0.000872	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—IL13—systemic scleroderma	0.000147	0.00252	CbGpPWpGaD
Lovastatin—Vision blurred—Prednisone—systemic scleroderma	0.000146	0.000866	CcSEcCtD
Lovastatin—Diarrhoea—Lisinopril—systemic scleroderma	0.000146	0.000863	CcSEcCtD
Lovastatin—Ill-defined disorder—Prednisone—systemic scleroderma	0.000144	0.000852	CcSEcCtD
Lovastatin—ITGAL—Extracellular matrix organization—TGFB1—systemic scleroderma	0.000144	0.00246	CbGpPWpGaD
Lovastatin—Angioedema—Prednisone—systemic scleroderma	0.000142	0.000839	CcSEcCtD
Lovastatin—ITGAL—Immune System—CTLA4—systemic scleroderma	0.000141	0.00242	CbGpPWpGaD
Lovastatin—Dizziness—Lisinopril—systemic scleroderma	0.000141	0.000835	CcSEcCtD
Lovastatin—Erythema multiforme—Methotrexate—systemic scleroderma	0.000141	0.000834	CcSEcCtD
Lovastatin—Nausea—Mycophenolic acid—systemic scleroderma	0.000141	0.000832	CcSEcCtD
Lovastatin—Malaise—Prednisone—systemic scleroderma	0.00014	0.000828	CcSEcCtD
Lovastatin—Vertigo—Prednisone—systemic scleroderma	0.000139	0.000825	CcSEcCtD
Lovastatin—HDAC2—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—systemic scleroderma	0.000139	0.00238	CbGpPWpGaD
Lovastatin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000138	0.000815	CcSEcCtD
Lovastatin—HMGCR—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000137	0.00234	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—SELP—systemic scleroderma	0.000137	0.00234	CbGpPWpGaD
Lovastatin—Vomiting—Lisinopril—systemic scleroderma	0.000136	0.000802	CcSEcCtD
Lovastatin—Rash—Lisinopril—systemic scleroderma	0.000134	0.000796	CcSEcCtD
Lovastatin—Dermatitis—Lisinopril—systemic scleroderma	0.000134	0.000795	CcSEcCtD
Lovastatin—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000134	0.000793	CcSEcCtD
Lovastatin—Chills—Methotrexate—systemic scleroderma	0.000134	0.000791	CcSEcCtD
Lovastatin—Headache—Lisinopril—systemic scleroderma	0.000134	0.000791	CcSEcCtD
Lovastatin—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000782	CcSEcCtD
Lovastatin—Myalgia—Prednisone—systemic scleroderma	0.000132	0.000782	CcSEcCtD
Lovastatin—Arthralgia—Prednisone—systemic scleroderma	0.000132	0.000782	CcSEcCtD
Lovastatin—Anxiety—Prednisone—systemic scleroderma	0.000132	0.000779	CcSEcCtD
Lovastatin—Alopecia—Methotrexate—systemic scleroderma	0.000132	0.000779	CcSEcCtD
Lovastatin—HDAC2—Regulation of Telomerase—TGFB1—systemic scleroderma	0.000131	0.00224	CbGpPWpGaD
Lovastatin—Discomfort—Prednisone—systemic scleroderma	0.000131	0.000772	CcSEcCtD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.00013	0.00223	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—NOS3—systemic scleroderma	0.000129	0.00221	CbGpPWpGaD
Lovastatin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000128	0.000757	CcSEcCtD
Lovastatin—HDAC2—Hemostasis—RHOB—systemic scleroderma	0.000128	0.00218	CbGpPWpGaD
Lovastatin—Dysgeusia—Methotrexate—systemic scleroderma	0.000127	0.000752	CcSEcCtD
Lovastatin—Nausea—Lisinopril—systemic scleroderma	0.000127	0.00075	CcSEcCtD
Lovastatin—Anaphylactic shock—Prednisone—systemic scleroderma	0.000127	0.00075	CcSEcCtD
Lovastatin—Infection—Prednisone—systemic scleroderma	0.000126	0.000745	CcSEcCtD
Lovastatin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	0.000126	0.00215	CbGpPWpGaD
Lovastatin—Back pain—Methotrexate—systemic scleroderma	0.000125	0.000742	CcSEcCtD
Lovastatin—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000124	0.000731	CcSEcCtD
Lovastatin—Vision blurred—Methotrexate—systemic scleroderma	0.000122	0.000723	CcSEcCtD
Lovastatin—Anorexia—Prednisone—systemic scleroderma	0.000121	0.000714	CcSEcCtD
Lovastatin—Ill-defined disorder—Methotrexate—systemic scleroderma	0.00012	0.000712	CcSEcCtD
Lovastatin—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000703	CcSEcCtD
Lovastatin—HDAC2—Direct p53 effectors—MMP2—systemic scleroderma	0.000118	0.00203	CbGpPWpGaD
Lovastatin—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	0.000118	0.00202	CbGpPWpGaD
Lovastatin—Rash—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000697	CcSEcCtD
Lovastatin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000118	0.000697	CcSEcCtD
Lovastatin—Headache—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000693	CcSEcCtD
Lovastatin—Malaise—Methotrexate—systemic scleroderma	0.000117	0.000692	CcSEcCtD
Lovastatin—Vertigo—Methotrexate—systemic scleroderma	0.000117	0.00069	CcSEcCtD
Lovastatin—ITGAL—Immune System—HLA-DQB1—systemic scleroderma	0.000116	0.00199	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—CSK—systemic scleroderma	0.000116	0.00199	CbGpPWpGaD
Lovastatin—Leukopenia—Methotrexate—systemic scleroderma	0.000116	0.000687	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000115	0.000683	CcSEcCtD
Lovastatin—Insomnia—Prednisone—systemic scleroderma	0.000115	0.000678	CcSEcCtD
Lovastatin—Paraesthesia—Prednisone—systemic scleroderma	0.000114	0.000673	CcSEcCtD
Lovastatin—Dyspepsia—Prednisone—systemic scleroderma	0.000112	0.00066	CcSEcCtD
Lovastatin—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000657	CcSEcCtD
Lovastatin—Arthralgia—Methotrexate—systemic scleroderma	0.00011	0.000653	CcSEcCtD
Lovastatin—Myalgia—Methotrexate—systemic scleroderma	0.00011	0.000653	CcSEcCtD
Lovastatin—Chest pain—Methotrexate—systemic scleroderma	0.00011	0.000653	CcSEcCtD
Lovastatin—ITGAL—Immune System—IL1A—systemic scleroderma	0.00011	0.00189	CbGpPWpGaD
Lovastatin—Decreased appetite—Prednisone—systemic scleroderma	0.00011	0.000652	CcSEcCtD
Lovastatin—ITGAL—Immune System—CD40LG—systemic scleroderma	0.00011	0.00188	CbGpPWpGaD
Lovastatin—Fatigue—Prednisone—systemic scleroderma	0.000109	0.000646	CcSEcCtD
Lovastatin—HDAC2—Hemostasis—ITGAM—systemic scleroderma	0.000109	0.00187	CbGpPWpGaD
Lovastatin—Discomfort—Methotrexate—systemic scleroderma	0.000109	0.000646	CcSEcCtD
Lovastatin—Constipation—Prednisone—systemic scleroderma	0.000108	0.000641	CcSEcCtD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000107	0.00184	CbGpPWpGaD
Lovastatin—Confusional state—Methotrexate—systemic scleroderma	0.000107	0.000632	CcSEcCtD
Lovastatin—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000106	0.000626	CcSEcCtD
Lovastatin—Infection—Methotrexate—systemic scleroderma	0.000105	0.000622	CcSEcCtD
Lovastatin—Feeling abnormal—Prednisone—systemic scleroderma	0.000104	0.000618	CcSEcCtD
Lovastatin—HMGCR—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000104	0.00178	CbGpPWpGaD
Lovastatin—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000104	0.000613	CcSEcCtD
Lovastatin—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000104	0.000613	CcSEcCtD
Lovastatin—Anorexia—Methotrexate—systemic scleroderma	0.000101	0.000597	CcSEcCtD
Lovastatin—Urticaria—Prednisone—systemic scleroderma	0.000101	0.000595	CcSEcCtD
Lovastatin—Body temperature increased—Prednisone—systemic scleroderma	0.0001	0.000593	CcSEcCtD
Lovastatin—Abdominal pain—Prednisone—systemic scleroderma	0.0001	0.000593	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	9.73e-05	0.00167	CbGpPWpGaD
Lovastatin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	9.65e-05	0.000571	CcSEcCtD
Lovastatin—Insomnia—Methotrexate—systemic scleroderma	9.58e-05	0.000567	CcSEcCtD
Lovastatin—Paraesthesia—Methotrexate—systemic scleroderma	9.51e-05	0.000562	CcSEcCtD
Lovastatin—HDAC2—Cell Cycle—TGFB1—systemic scleroderma	9.45e-05	0.00162	CbGpPWpGaD
Lovastatin—Dyspnoea—Methotrexate—systemic scleroderma	9.44e-05	0.000558	CcSEcCtD
Lovastatin—Hypersensitivity—Prednisone—systemic scleroderma	9.33e-05	0.000552	CcSEcCtD
Lovastatin—Dyspepsia—Methotrexate—systemic scleroderma	9.32e-05	0.000551	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	9.24e-05	0.00158	CbGpPWpGaD
Lovastatin—Decreased appetite—Methotrexate—systemic scleroderma	9.2e-05	0.000545	CcSEcCtD
Lovastatin—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	9.19e-05	0.00157	CbGpPWpGaD
Lovastatin—Fatigue—Methotrexate—systemic scleroderma	9.13e-05	0.00054	CcSEcCtD
Lovastatin—Asthenia—Prednisone—systemic scleroderma	9.09e-05	0.000538	CcSEcCtD
Lovastatin—Pain—Methotrexate—systemic scleroderma	9.05e-05	0.000536	CcSEcCtD
Lovastatin—Pruritus—Prednisone—systemic scleroderma	8.96e-05	0.00053	CcSEcCtD
Lovastatin—Feeling abnormal—Methotrexate—systemic scleroderma	8.72e-05	0.000516	CcSEcCtD
Lovastatin—Diarrhoea—Prednisone—systemic scleroderma	8.67e-05	0.000513	CcSEcCtD
Lovastatin—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.66e-05	0.000512	CcSEcCtD
Lovastatin—HDAC2—Gene Expression—SMAD7—systemic scleroderma	8.59e-05	0.00147	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—TGFB1—systemic scleroderma	8.53e-05	0.00146	CbGpPWpGaD
Lovastatin—Urticaria—Methotrexate—systemic scleroderma	8.41e-05	0.000498	CcSEcCtD
Lovastatin—Dizziness—Prednisone—systemic scleroderma	8.38e-05	0.000496	CcSEcCtD
Lovastatin—Abdominal pain—Methotrexate—systemic scleroderma	8.37e-05	0.000495	CcSEcCtD
Lovastatin—Body temperature increased—Methotrexate—systemic scleroderma	8.37e-05	0.000495	CcSEcCtD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	8.27e-05	0.00142	CbGpPWpGaD
Lovastatin—Vomiting—Prednisone—systemic scleroderma	8.06e-05	0.000477	CcSEcCtD
Lovastatin—HDAC2—Gene Expression—TNFSF13—systemic scleroderma	7.99e-05	0.00137	CbGpPWpGaD
Lovastatin—Rash—Prednisone—systemic scleroderma	7.99e-05	0.000473	CcSEcCtD
Lovastatin—Dermatitis—Prednisone—systemic scleroderma	7.98e-05	0.000472	CcSEcCtD
Lovastatin—HDAC2—Disease—SMAD7—systemic scleroderma	7.98e-05	0.00137	CbGpPWpGaD
Lovastatin—Headache—Prednisone—systemic scleroderma	7.94e-05	0.00047	CcSEcCtD
Lovastatin—Hypersensitivity—Methotrexate—systemic scleroderma	7.8e-05	0.000462	CcSEcCtD
Lovastatin—Asthenia—Methotrexate—systemic scleroderma	7.6e-05	0.000449	CcSEcCtD
Lovastatin—Nausea—Prednisone—systemic scleroderma	7.53e-05	0.000445	CcSEcCtD
Lovastatin—Pruritus—Methotrexate—systemic scleroderma	7.49e-05	0.000443	CcSEcCtD
Lovastatin—HDAC2—Disease—TGFBI—systemic scleroderma	7.3e-05	0.00125	CbGpPWpGaD
Lovastatin—Diarrhoea—Methotrexate—systemic scleroderma	7.24e-05	0.000429	CcSEcCtD
Lovastatin—UGT1A3—NRF2 pathway—TGFB1—systemic scleroderma	7.23e-05	0.00124	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	7.07e-05	0.00121	CbGpPWpGaD
Lovastatin—Dizziness—Methotrexate—systemic scleroderma	7e-05	0.000414	CcSEcCtD
Lovastatin—Vomiting—Methotrexate—systemic scleroderma	6.73e-05	0.000398	CcSEcCtD
Lovastatin—Rash—Methotrexate—systemic scleroderma	6.68e-05	0.000395	CcSEcCtD
Lovastatin—Dermatitis—Methotrexate—systemic scleroderma	6.67e-05	0.000395	CcSEcCtD
Lovastatin—Headache—Methotrexate—systemic scleroderma	6.63e-05	0.000392	CcSEcCtD
Lovastatin—Nausea—Methotrexate—systemic scleroderma	6.29e-05	0.000372	CcSEcCtD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.26e-05	0.00107	CbGpPWpGaD
Lovastatin—UGT2B7—NRF2 pathway—TGFB1—systemic scleroderma	6.15e-05	0.00105	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—HSPG2—systemic scleroderma	6.1e-05	0.00104	CbGpPWpGaD
Lovastatin—HDAC2—Disease—HSPG2—systemic scleroderma	5.82e-05	0.000997	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—IL1B—systemic scleroderma	5.76e-05	0.000986	CbGpPWpGaD
Lovastatin—HDAC2—Disease—CSK—systemic scleroderma	5.62e-05	0.000963	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—SMAD7—systemic scleroderma	5.59e-05	0.000957	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—MMP1—systemic scleroderma	5.47e-05	0.000937	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	5.36e-05	0.000917	CbGpPWpGaD
Lovastatin—HDAC2—Disease—CD247—systemic scleroderma	5.29e-05	0.000905	CbGpPWpGaD
Lovastatin—UGT1A1—NRF2 pathway—TGFB1—systemic scleroderma	5e-05	0.000855	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—HSPG2—systemic scleroderma	4.97e-05	0.000851	CbGpPWpGaD
Lovastatin—ABCC2—NRF2 pathway—TGFB1—systemic scleroderma	4.87e-05	0.000834	CbGpPWpGaD
Lovastatin—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	4.82e-05	0.000825	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—CTGF—systemic scleroderma	4.75e-05	0.000814	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—CTGF—systemic scleroderma	4.62e-05	0.000791	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—RHOB—systemic scleroderma	4.32e-05	0.00074	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—HSPG2—systemic scleroderma	4.23e-05	0.000724	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—HSPG2—systemic scleroderma	4.08e-05	0.000698	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.06e-05	0.000695	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—NOS3—systemic scleroderma	3.97e-05	0.000679	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CSK—systemic scleroderma	3.94e-05	0.000674	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—CTGF—systemic scleroderma	3.77e-05	0.000645	CbGpPWpGaD
Lovastatin—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	3.75e-05	0.000641	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—HSPG2—systemic scleroderma	3.68e-05	0.00063	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.63e-05	0.000621	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—HSPG2—systemic scleroderma	3.43e-05	0.000588	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.31e-05	0.000566	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—CTGF—systemic scleroderma	3.2e-05	0.000549	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—HSPG2—systemic scleroderma	3.15e-05	0.000539	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.08e-05	0.000527	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—HSPG2—systemic scleroderma	2.89e-05	0.000495	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—CTGF—systemic scleroderma	2.79e-05	0.000478	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.75e-05	0.00047	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—TGFB1—systemic scleroderma	2.62e-05	0.000449	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—CTGF—systemic scleroderma	2.6e-05	0.000446	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.51e-05	0.000429	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—CTGF—systemic scleroderma	2.39e-05	0.000408	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—EDN1—systemic scleroderma	2.21e-05	0.000378	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—CTGF—systemic scleroderma	2.19e-05	0.000375	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—HSPG2—systemic scleroderma	2.09e-05	0.000358	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—NOS3—systemic scleroderma	2.01e-05	0.000344	CbGpPWpGaD
Lovastatin—HDAC2—Disease—NOS3—systemic scleroderma	1.92e-05	0.000329	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	1.85e-05	0.000316	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—HSPG2—systemic scleroderma	1.81e-05	0.00031	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—NOS3—systemic scleroderma	1.64e-05	0.000281	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—HSPG2—systemic scleroderma	1.61e-05	0.000276	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—CTGF—systemic scleroderma	1.58e-05	0.000271	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—HSPG2—systemic scleroderma	1.58e-05	0.00027	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CCL2—systemic scleroderma	1.51e-05	0.000258	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—HSPG2—systemic scleroderma	1.48e-05	0.000254	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—HSPG2—systemic scleroderma	1.47e-05	0.000252	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—NOS3—systemic scleroderma	1.39e-05	0.000239	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—CTGF—systemic scleroderma	1.37e-05	0.000235	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—NOS3—systemic scleroderma	1.34e-05	0.00023	CbGpPWpGaD
Lovastatin—HDAC2—Disease—TGFB1—systemic scleroderma	1.27e-05	0.000217	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—CTGF—systemic scleroderma	1.22e-05	0.000209	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—NOS3—systemic scleroderma	1.21e-05	0.000208	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—CTGF—systemic scleroderma	1.19e-05	0.000204	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—NOS3—systemic scleroderma	1.13e-05	0.000194	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—CTGF—systemic scleroderma	1.13e-05	0.000193	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—CTGF—systemic scleroderma	1.12e-05	0.000191	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MMP9—systemic scleroderma	1.08e-05	0.000185	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—NOS3—systemic scleroderma	1.04e-05	0.000178	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—HSPG2—systemic scleroderma	9.71e-06	0.000166	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—NOS3—systemic scleroderma	9.53e-06	0.000163	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TGFB1—systemic scleroderma	8.89e-06	0.000152	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—CTGF—systemic scleroderma	7.36e-06	0.000126	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—NOS3—systemic scleroderma	6.89e-06	0.000118	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—NOS3—systemic scleroderma	5.97e-06	0.000102	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—NOS3—systemic scleroderma	5.33e-06	9.12e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—NOS3—systemic scleroderma	5.2e-06	8.9e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—NOS3—systemic scleroderma	4.9e-06	8.39e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—NOS3—systemic scleroderma	4.86e-06	8.31e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—NOS3—systemic scleroderma	3.2e-06	5.48e-05	CbGpPWpGaD
